efficacy of teclistimab versus current treatments in patients with triple-class exposed rr myeloma
Published 2 years ago • 278 plays • Length 5:41Download video MP4
Download video MP3
Similar videos
-
1:43
safety and efficacy of teclistamab in patients with triple-class exposed r/r myeloma
-
11:22
updated efficacy/safety results of majestec-1 (teclistamab) at asco 2022
-
1:27
comparative efficacy of teclistamab vs pom dex in triple-class exposed r/r myeloma
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
8:12
evaluating teclistamab in relapsed and/or refractory multiple myeloma
-
2:04
approval of teclistamab in triple-class refractory multiple myeloma
-
7:04
safety and efficacy of elranatamab in rrmm & prior bcma therapies: analysis from magnetismm studies
-
1:14
clinical benefit of teclistamab vs real-world physician’s choice for r/r multiple myeloma
-
5:06
durability of responses with biweekly dosing of teclistamab in pts with relapsed/refractory myeloma
-
6:27
clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma
-
1:08
safety and efficacy of iberdomide dexamethasone in patients with triple-class refractory myeloma
-
4:56
updates on phase 1b trimm-2 study results of teclistamab daratumumab presented at eha 2022
-
0:45
majestec-2 update: teclistamab plus lenalidomide in r/r multiple myeloma
-
4:30
majestec-1: longer follow-up teclistamab tocilizumab prophylaxis for crs in rr multiple myeloma
-
14:31
teclistamab - guest lecture
-
6:58
phase 1 study of the gprc5dxcd3 bispecific talquetamab in patients with rr multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
8:43
results from monumental-1: first-in-human study of talquetamab in pts with rr multiple myeloma